Optimal Management of Newly Diagnosed CKD (Not on Dialysis)
Start all patients aged ≥50 years with eGFR <60 ml/min/1.73m² on a statin or statin/ezetimibe combination immediately, and initiate SGLT2 inhibitor therapy for those with proteinuria regardless of diabetes status 1, 2.
Core Pharmacologic Interventions
Cardiovascular Protection (Mandatory)
Statin therapy is the foundation and must be initiated based on age and kidney function:
- Age ≥50 with eGFR <60: Statin or statin/ezetimibe combination (strongest recommendation, 1A evidence) 1, 2
- Age ≥50 with eGFR ≥60: Statin alone (1B evidence) 1, 2
- Age 18-49: Statin if any of the following exist: known coronary disease, diabetes, prior stroke, or 10-year CV risk >10% 1, 2
Maximize LDL reduction by choosing high-intensity statin regimens. Consider PCSK-9 inhibitors when indicated 1, 2.
Kidney Protection (Disease-Modifying Therapy)
SGLT2 inhibitors are now standard of care for CKD with proteinuria, with or without diabetes 3, 4. These agents directly slow progression and reduce cardiovascular events. The evidence supporting SGLT2i use represents a paradigm shift in nephroprotection 5, 3.
RAAS inhibitors (ACE inhibitors or ARBs) remain essential for blood pressure control and proteinuria reduction 3, 4. These should be optimized to maximum tolerated doses.
For patients with type 2 diabetes and CKD, add finerenone (nonsteroidal mineralocorticoid receptor antagonist) for additional kidney protection 3, 4. GLP-1 receptor agonists provide both glycemic control and kidney-protective effects in this population 5, 3, 4.
Blood Pressure Management
Target blood pressure control using RAAS inhibitors as first-line agents, supplemented with calcium channel blockers as needed 6, 3. The combination reduces both cardiovascular risk and CKD progression.
Antiplatelet Therapy
Use low-dose aspirin only for secondary prevention in patients with established ischemic cardiovascular disease (1C recommendation) 1, 2. Do not use aspirin for primary prevention in CKD. Consider P2Y12 inhibitors if aspirin intolerance exists 2.
Metabolic Management
Hyperkalemia Prevention
Implement dietary potassium restriction for patients with CKD G3-G5 who have hyperkalemia history, focusing on limiting processed foods rich in bioavailable potassium 1, 2. Involve a renal dietitian for individualized assessment 1, 2.
Novel potassium binders enable optimal RAAS inhibitor use and facilitate plant-based diets, which provide beneficial micronutrients, antioxidants, and fiber 5.
Hyperuricemia
Treat symptomatic hyperuricemia (gout) with uric acid-lowering therapy using xanthine oxidase inhibitors (preferred over uricosurics) 1, 2. For acute gout, use low-dose colchicine or glucocorticoids instead of NSAIDs 1, 2.
Do not treat asymptomatic hyperuricemia to delay CKD progression (2D recommendation against this practice) 1, 2.
Glycemic Control (if diabetic)
Prioritize SGLT2 inhibitors and GLP-1 receptor agonists for their dual benefits on glycemic control and cardiorenal protection 6, 3, 4. These agents counterbalance hyperfiltration and provide nephroprotection beyond glucose lowering 5.
Dietary Interventions
Adopt a plant-based Mediterranean-style diet in addition to pharmacologic therapy to reduce cardiovascular risk 1, 2. This dietary pattern complements lipid-lowering medications.
Consider low-protein diets supplemented with ketoanalogues to delay CKD progression and control metabolic disturbances 6. However, SGLT2 inhibitors now allow more dietary flexibility by counterbalancing the effects of higher protein intake 5.
Restrict dietary sodium to prevent volume overload and support blood pressure control 6.
Nephrotoxin Avoidance (Critical)
Strictly avoid NSAIDs, minimize proton pump inhibitors, avoid aminoglycosides, and use contrast media judiciously 6, 4. Implement nephrotoxin stewardship through patient education on sick-day medication management 4.
Monitoring Strategy
Measure albumin-to-creatinine ratio (ACR) and check for hematuria at initial diagnosis 7. Use validated GFR equations, incorporating serum cystatin C for specific populations 4.
Establish monitoring intervals based on CKD stage, comorbidities, and rate of progression 7. Use the Kidney Failure Risk Equation to identify high-risk patients requiring nephrology referral 3.
Nephrology Referral Triggers
Refer when:
- eGFR <30 ml/min/1.73m²
- Newly diagnosed CKD with eGFR 30-59 + persistent unexplained hematuria or albuminuria ≥A2
- Refractory hypertension requiring ≥3 antihypertensive drugs
- Rapidly progressive kidney disease
- Age <50 (lower threshold for referral)
- Age >70 only if warranted by comorbidities and health goals 7
Common Pitfalls
Do not delay SGLT2 inhibitor initiation while waiting for "optimal" RAAS inhibitor dosing—these therapies work synergistically and should be started concurrently 3, 4.
Do not use aspirin for primary prevention—the bleeding risk outweighs benefits in CKD without established cardiovascular disease 1, 2.
Do not treat asymptomatic hyperuricemia—this does not slow CKD progression and exposes patients to unnecessary medication 1, 2.
Avoid the trap of overly restrictive diets—modern pharmacotherapy (SGLT2i, potassium binders) enables more permissive, nutritionally complete eating patterns 5.